Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin and Everolimus in Triple Negative Metastatic Breast Cancer
NCT02120469Phase 1Completed
- Sponsor
- City of Hope
- Start
- Nov 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus and eribulin in triple-negative breast cancer (TNBC), sponsored by City of Hope. Primary endpoints: Number of Participants Experiencing a Dose Limiting Toxicity at 21 days, Recommended Phase IB Dose at 21 days and 1 more. Started Nov 2014; status: completed.
02
Drugs
everolimuseribulin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02120469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120469.